PATENT CLAIM ANALYSIS

Application Number: 16170634
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-08
Patent Classification: ["514", "365000"]

Abstract:
The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (CSCPK) and related kinases, and methods of using these compounds, to treat subjects in need thereof.

Claim (Index 1):
A method of treating a cancer in a human subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure: or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the compound is administered to the subject at a total daily dose of about 300 mg.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.13333
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15114465', '13634694', '13634676', '14642931', '15981406']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6895961886997936
- 35 USC 102 Novelty (BERT): 0.5025977079583255
- Combined Prediction Score: 0.6708963406256467
- Mean Citation Score: 217.763142
- Max Citation Score: 264.90932999999995
- Similarity Product: 201.02242874496457

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test